Literature DB >> 21498670

Identification and characterization of a novel transcriptional target of RUNX1/AML1 at the onset of hematopoietic development.

Cristina Ferreras1, Christophe Lancrin, Michael Lie-A-Ling, Valerie Kouskoff, Georges Lacaud.   

Abstract

Although the critical requirement for the transcription factor RUNX1/AML1 at the onset of hematopoietic development is well established, little is known about its transcriptional targets at this pivotal stage of blood development. Using microarrays, we identified the uncharacterized gene AI467606 as a gene whose expression level is dramatically reduced in the absence of RUNX1. We further demonstrated by chromatin immunoprecipitation and promoter assay a direct regulation of its transcription by RUNX1. Using a bacterial artificial chromosome transgenic approach, we established that AI467606 is expressed during the development of the hematopoietic system in vivo and in vitro and that its expression is detected within the CD41(+) population and marks definitive hematopoietic potential. Similarly, in the adult mouse, all hematopoietic cell lineages, except mature erythrocytes, express AI467606. Taken together, these findings indicate that AI467606 is a novel transcriptional target of RUNX1/AML1 at the onset of hematopoietic development that is extensively expressed within the hematopoietic system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498670     DOI: 10.1182/blood-2010-06-294124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells.

Authors:  Kiran Batta; Magdalena Florkowska; Valerie Kouskoff; Georges Lacaud
Journal:  Cell Rep       Date:  2014-11-26       Impact factor: 9.423

2.  A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.

Authors:  S Y Kim; J-W Theunissen; J Balibalos; S Liao-Chan; M C Babcock; T Wong; B Cairns; D Gonzalez; E H van der Horst; M Perez; Z Levashova; L Chinn; J A D'Alessio; M Flory; A Bermudez; D Y Jackson; E Ha; J Monteon; M F Bruhns; G Chen; T-S Migone
Journal:  Blood Cancer J       Date:  2015-05-29       Impact factor: 11.037

3.  Genomic deletion of GIT2 induces a premature age-related thymic dysfunction and systemic immune system disruption.

Authors:  Sana Siddiqui; Ana Lustig; Arnell Carter; Mathavi Sankar; Caitlin M Daimon; Richard T Premont; Harmonie Etienne; Jaana van Gastel; Abdelkrim Azmi; Jonathan Janssens; Kevin G Becker; Yongqing Zhang; William Wood; Elin Lehrmann; James G Martin; Bronwen Martin; Dennis D Taub; Stuart Maudsley
Journal:  Aging (Albany NY)       Date:  2017-03-04       Impact factor: 5.682

4.  Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium.

Authors:  Michael Lie-A-Ling; Elli Marinopoulou; Andrew J Lilly; Mairi Challinor; Rahima Patel; Christophe Lancrin; Valerie Kouskoff; Georges Lacaud
Journal:  Development       Date:  2018-03-12       Impact factor: 6.868

5.  Efficient hemogenic endothelial cell specification by RUNX1 is dependent on baseline chromatin accessibility of RUNX1-regulated TGFβ target genes.

Authors:  Elizabeth D Howell; Amanda D Yzaguirre; Peng Gao; Raphael Lis; Bing He; Melike Lakadamyali; Shahin Rafii; Kai Tan; Nancy A Speck
Journal:  Genes Dev       Date:  2021-10-21       Impact factor: 11.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.